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Mark G. Davies, MD, PhD, MBA, Wael E. Saad, MD, Jean Bismuth, MD, Joseph J. Naoum, MD,
Eric K. Peden, MD, and Alan B. Lumsden, MD, Houston, Tex
Background: The intent of endovascular therapy for symptomatic atherosclerotic renal artery stenosis (ARAS) is to
preserve parenchyma and avoid renal-related morbidity. The aim of this study is to examine the impact of renal artery
intervention on parenchymal preservation.
Methods: We performed a retrospective analysis of records from patients who underwent endovascular intervention for
ARAS and were followed by duplex ultrasound between 1990 and 2008. Renal volume (in cm3) was estimated in all
patients as renal length (cm)  renal width (cm)  renal depth (cm)  0.5. The normal renal volume was calculated as
2  body weight (kg) in cm3. Failure of preservation was considered to be a persistent 10% decrease in volume. Clinical
benefit defined as freedom from renal-related morbidity (increase in persistent creatinine >20% of baseline, progression
to hemodialysis, death from renal-related causes) was calculated.
Results: Five hundred ninety-two renal artery interventions were performed. One hundred eighty-six kidneys suffered
parenchymal loss (>5%) with an actuarial parenchymal loss rate of 29%  1% at five years respectively. There were no
significant differences in age, gender, starting renal volume, or kidney size. However, patients with parenchymal loss had
lower eGFR (45  24 vs 53  24 mL/min/1.73 m2; Loss vs noLoss, P  .0002, Mean  SD) higher resistive index
(0.75  0.9 vs 0.73  0.10; P  .0001) and worse nephrosclerosis grade (1.43  0.55 vs 1.30  0.49; P  .006) then
those not suffering parenchymal loss. Parenchymal loss was associated with significantly worse five-year survival (26% 
4% vs 48% 2%; Loss vs noLoss; P< .001) and freedom from renal-related morbidity (70% 5% vs 82% 2%; P< .05)
with increased numbers progressing to dialysis (17% vs 7%; P < .006).
Conclusion: While parenchymal preservation occurs in most patients, parenchymal loss occurs in 31% of patients and is
associated with markers of impaired parenchymal perfusion (resistive index and nephrosclerosis grade) at the time of
intervention. Pre-existing renal size or volumes were not predictive of parenchymal loss. Parenchymal loss is associated
with a significant decrease in survival and a marked increased renal related morbidity and progression to hemodialysis.
(J Vasc Surg 2010;51:1222-9.)Protection of renal parenchyma is a goal of therapy in
renal interventions for symptomatic atherosclerotic renal
artery stenosis, whether it is for hypertension or renal
insufficiency. In the well-selected patient, renal interven-
tion appears to be effective in controlling hypertension and
controlling deteriorating renal function. Long-term free-
dom from renal-related morbidity appears not to be sus-
tainable and is influenced by the estimated Glomerular
Filtration Rate (eGFR)1-3 and the pre-operative rate of
decrease in renal function prior to intervention.4,5 Paren-
chymal loss has most often been determined by pole-to-
pole length of the kidney on ultrasound. This, however,
only measures one dimension of a three dimensional organ.
Kidneys with 50% renal artery stenosis have been shown
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1222to suffer a loss of parenchymal volume (33%) with no
significant reduction in pole to pole length.6 Parenchymal
volume has been shown to be a better predictor of single
kidney GFR than length.7 The aim of this study is to
examine the impact of renal artery intervention on paren-
chymal preservation and determine those factors which
influence the outcomes.
METHODS
Study design. A retrospective analysis of records from
patients who underwent endovascular intervention for
ARAS and were followed by duplex ultrasound between
1990 and 2008 was performed. Renal volume (in cm3) was
estimated in all patients as renal length (cm)  renal width
(cm)  renal depth (cm)  0.5.8 For each patient, demo-
graphics, existing comorbid conditions, and risk factors for
atherosclerosis were identified. The normal renal volume
was calculated as 2  body weight (kg) in cm3.8 Failure of
preservation was considered to be a persistent 10% decrease
in volume in two consecutive scans. Patients were catego-
rized into a Loss or noLoss group based on this criterion for
parenchymal loss. Clinical benefit, defined as freedom from
renal-related morbidity (increase in persistent creatinine
20% of baseline, progression to hemodialysis, death from
renal-related causes), was calculated.
Treatment algorithm. Patients with hypertension
underwent a diagnostic study to identify the presence of
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giography, magnetic resonance angiography, renal isotope
scan, or duplex ultrasound. Duplex ultrasound criteria to
identify renal artery stenosis have been previously de-
scribed.1-3,9 In the presence of the clinical criteria defined
by Rundback et al10 and a 60% stenosis on ultrasound or
50% stenosis on magnetic resonance angiography or
cross-sectional tomographic angiography, conventional an-
giography was performed. The majority of these interven-
tions were transfemoral and no distal protection devices
were used. In the presence of bilateral disease, each renal
artery was considered individually. The majority of bilateral
renal artery interventions were staged with a 30-day interval
between procedures. Occluded renal arteries and nonfunc-
tioning kidneys were not treated. Patients with creatinine
1.5 mg/mL were hydrated overnight with normal saline
and those treated within the last five years received muco-
myst 600 mg twice a day orally 24 hours preoperatively and
for 48 hours postoperatively. Less renal toxic non ionic
contrasts and low profile delivery systems were also intro-
duced in the last 10 years of the study. These changes were
equally distributed between the two groups. Patients were
followed at six-month intervals after the procedure. Blood
pressure, serum creatinine, and number of antihypertensive
medications were identified during these intervals. Each
patient had at least one duplex ultrasound within six
months of the procedure and an ultrasound every six
months thereafter to assess renal dimensions and patency.
Ninety percent of patients had a duplex at their final office
follow up. If the duplex ultrasound showed 60% stenosis
and the patient had recurrent symptoms, angiography was
performed and restenosis was treated if the arterial diameter
was 50%.
Definitions. Parenchymal loss was defined as a 10%
decrease in volume, which is equivalent to 1 cm decrease of
a 9 cm kidney. Hypercholesterolemia was defined as fasting
cholesterol200mg/dL. Diabetes was defined as a fasting
plasma glucose110 mg/dL) or an HbA1c7%. Diabet-
ics were characterized as IDDM (Insulin dependent diabe-
tes mellitus) or NIDDM (Non-insulin dependent diabetes
mellitus). Metabolic syndrome was defined as previously de-
scribed11 (insulin resistance or impaired glucose tolerance,
hypertension, dyslipidemia, and abdominal obesity). Hy-
pertension was defined as diastolic blood pressure greater
than 90 mm Hg on more than three antihypertensive
medications). An elevated creatinine was defined as 1.5
mg/dl on two consecutive values during a three-month
period. Chronic renal insufficiency was defined as a persis-
tent serum creatinine 1.5 mg/dl for greater than six
months. Estimated glomerular filtration rate (eGFR) was
defined as 186.3* serum creatinine1.154* age0.203*
0.742 (if female) *1.212 (if African American). The base-
line serum creatinine level was the value recorded closest to
the procedure. Patients were considered to have a “non-
functioning kidney” if any two of the following local crite-
ria used at our institution over the time of the study were
met: (1) a duplex ultrasound scan identified a pole-to-pole
length of less than 9 cmwith no renal flow in the main renalartery and parenchymal peak systolic velocity 10 cm/s;
(2) surgically or congenitally absent kidney; (3) no visible
nephrogram on contrast arteriogram. A normal contralat-
eral kidney was considered a kidney without evidence of
50% renal artery stenosis and not fulfilling criteria for a
“nonfunctioning kidney.” Renal Resistive Index was de-
fined from duplex imaging as 1-[EDV/PSV]*100. Ne-
phrosclerosis was defined as Grade 1: Normal intrarenal
vessels, orderly progression of branching patterns (no prun-
ing), normal nephrogram with distinct corticomedullary
junction; Grade 2: Ectasia of arcuate and distal interlobular
arteries, peripheral pruning, reduced arterial volume with
normal renal mass, normal nephrogram; Grade 3: marked
ectasia extending centrally, total pruning with abrupt inter-
lobar artery terminations, marked reduced arterial volume
with decreased renal mass, faint absent nephrogram.12 An
endoluminal procedural success was a residual stenosis of
30%; failures were residual stenosis 30%, by angio-
graphic measurement, including lesions unable to be di-
lated or crossed and occlusion within 30 days. A death
within 30 days of the procedure was considered procedure-
related. Acute functional renal injury was defined as a
persistent increase in the serum creatinine of 0.5 mg/dl
at one month after the procedure. Acute anatomic renal
injury was defined as renal artery dissection, perforation,
acute occlusion, renal parenchymal infarction, and renal
parenchymal perforation. Access site complication was de-
fined as hematoma, pseudoaneurysms, arteriovenous fis-
tula, or a vessel injury requiring either percutaneous or
open intervention. Systemic complications were any new
cardiac, pulmonary, infectious, or non-renal systemic com-
plication that required intervention or halted discharge
within 24 hours of the procedure or required readmission
within 30 days of the procedure. Response in the hyperten-
sive patient was defined as follows: “cured” patients were
normotensive (diastolic blood pressure 90 mm Hg and
systolic blood pressure 140 mm Hg) without medica-
tions; “improved” patients were normotensive (diastolic
blood pressure90mmHg and/or systolic blood pressure
140 mm Hg) on the same (or reduced) number of
medications or had a diastolic blood pressure 15 mm Hg
below baseline with the same or reduced number of medi-
cations. “No effect” patients had no change or the inability
to meet these criteria for cure or improvement and were
considered a treatment failure. Early renal function re-
sponses to angioplasty were defined as follows: “cured”
renal function required a serum creatinine concentration
1.5 mg/dL; “improvement” in renal function required a
20% reduction in the serum creatinine concentration;
“stable” renal function required a20% increase or reduc-
tion in the serum creatinine concentration; “deterioration”
in renal function required a 20% increase in the serum
creatinine concentration.10 Non reversal of a recent de-
crease in renal function or deterioration of renal function
were considered treatment failures. Freedom from renal
related morbidity was defined as a persistent increase in
creatinine 20% of baseline, progression to hemodialy-
sis, death from renal-related causes.10
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“intention to treat” basis. With regard to patency and
parenchymal loss, we analyzed each kidney treated. With
regard to patient outcomes, we used the renal artery with
the greatest stenosis, if bilateral interventions were per-
formed, as the kidney at risk for parenchymal loss in follow
up. Renal images were graded by two blinded observers
with low intra-observer variability. Measured values are
reported as percentages or means 1 standard deviation.
Mann-Whitney tests were used to test the difference be-
tween means. Fischer’s or Chi-squared tests were per-
formed to test the significance between proportions in each
group. Survival and clinical benefit rates are calculated
using life table analysis and reported using the Society for
Vascular Surgery (SVS) criteria. Standard errors are re-
ported in actuarial analyses. The log rank test was used to
determine differences between life tables. Analyses were
performed using JMP software version 7.0 (SAS Institute,
Cary, North Carolina, USA). Cox proportional hazards
models were employed for time dependent outcomes by
preprocedural variables and periprocedural variables.
RESULTS
Patient population. Five hundred ninety-two renal
artery interventions were performed. There were no signif-
icant differences in age or gender between the patients with
(Loss) and without parenchymal loss loss (noLoss) (Table
I). Patients with parenchymal loss were more likely to have
an elevated creatinine as an indication for therapy com-
pared with those who demonstrated long-term parenchy-
mal preservation (Table I). Patients with parenchymal loss
were associated with a greater incidence of diabetes mellitus
Table I. Patients’ characteristics, presenting symptoms,
and co-morbidities
No
parenchymal
loss
Parenchymal
loss P value
Demographics
Patients 264 123 —
Kidneys 406 186 —
Male 55% 49% .17
Average age (mean 
SD, years) 70  11 71  9 .24
Symptoms
Hypertension 63% 51% .012
Elevated creatinine 9% 16%
Hypertension with
elevated creatinine 22% 24%
Co-morbidities
Smoking history 66% 54% .0043
Diabetes mellitus 29% 37% .051
Hyperlipidemia 71% 63% .051
Statin use 72% 71% .81
Metabolic syndrome 53% 50% .50
Follow-up
Follow up (median
[range], years) 3.3 (1-14) 1.9 (1-12) .0001but were less likely to be current smokers or to havehyperlipidemia (Table I). Metabolic syndrome and statin
use was equivalent between the two groups (Table I).
Those patients who did not suffer parenchymal loss had a
lower mean serum creatinine concentration and higher
mean eGFR (Table II). The distribution of stages of
chronic kidney disease and eGFR were worse in the
patients suffering parenchymal loss (Table II). The status
of the contralateral kidney was equivalent. Anatomically,
kidney size and the starting kidney volume were equiva-
lent between the two groups (Table II). However,
patients with parenchymal loss had a higher resistive index
(0.75 0.08 vs 0.73 0.10, Loss and noLoss; P .0001)
and worse nephrosclerosis grade (1.43  0.55 vs 1.30 
0.49; P  .006) than those without parenchymal loss
(Table I). At the time of intervention, 59% of the ipsilateral
kidneys that demonstrated parenchymal loss had a resistive
index 0.8 compared with 50% of the ipsilateral kidneys
without parenchymal loss. Nephrosclerosis grade of2was
Table II. Kidney disease, creatinine levels, estimated
GFR, ipsilateral and contralateral hemodynamic, and
anatomy parameters
No parenchymal
loss
Parenchymal
loss
P
value
Kidney Disease Stage
1 7% 5% .0004
2 22% 14%
3 56% 52%
4 13% 22%
5 2% 8%
Functional Parameters
Creatinine (mg/dL) 1.6  0.86 1.9  1.1 .001
Mean eGFR mL/
min/1.73 m2 52  24 45  24 .0002
eGFR 30
mL/min/1.73 m2 15% 29% .0001
eGFR 30-60 mL/
min/1.73 m2 58% 52%
eGFR 60
mL/min/1.73 m2 29% 19%
Ipsilateral kidney
anatomy
Kidney length (cm) 10.2  1.4 10.2  1.1 .9
Kidney volume (cm3) 134.2  14.9 133.5  13.8 .59
Kidney volume (%
normal) 90  19 90  17 .8
Resistive index 0.73  0.10 0.75  0.08 .0001
Nephrosclerosis 1.30  0.49 1.43  0.55 .006
Contralateral kidney
anatomy
Normal 46% 34% —
Stenosis (60%) 7% 13% —
Stenosis (60%) 37% 35% —
Non-functioning 9% 15% —
Surgically absent 1% 3% —
Contralateral kidney
parameters
Kidney length (cm) 10.0  1.4 9.7  1.4 .016
Resistive index 0.72  0.10 0.74  0.10 .025
Nephrosclerosis 1.34  0.59 1.63  0.70 .0001seen in 40% of the ipsilateral kidneys that demonstrated
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kidneys without parenchymal loss.
Outcomes (<3 months). The technical failure rate
was equivalent in both groups at 5% and 6% for Loss and
noLoss, respectively. There were significant differences in
the 30-day (4.3% vs 0.2%) and 90-day (8.6% vs 0.5%, Loss
and noLoss) mortalities between the Loss and noLoss
groups, respectively, with significantly more patients dying
early in the Loss group. The majority of these deaths were
cardiopulmonary. The procedure-related complication rate
for this group was 16% and 21% between the Loss and
noLoss groups, respectively, which was not significant (Ta-
ble III). The nature of the renal interventions and catego-
ries of complications in both groups are shown in Table III
and were equivalent. There was a significant difference in
acute functional injury between the Loss (25%) and noLoss
(16%) groups, respectively (Table III). Ten percent of
patients in the noLoss group demonstrated immediate
clinical benefit of improved or cured renal dysfunction and
80% showed no change within three months of procedure
(Table IV). In contrast, 6% of patients in the Loss group
demonstrated immediate clinical benefit of improved or
cured renal dysfunction and 82% showed no change within
three months of procedure (Table IV). These differences in
Table III. Interventions
No
parenchymal
loss
Parenchymal
loss
P
value
Interventions
Angioplasty 23% 28% .18
Predilation 29% 14%
Stent placement 77% 72%
Contralateral intervention 35% 34% .79
Repeat ipsilateral
intervention 7% 9% .33
Complications
Acute functional injury 16% 25% 0.008
Anatomic injury 6% 8% 0.32
Access site 8% 10% 0.35
Systemic 2% 3% 0.35
Table IV. Outcomes
No
parenchymal
loss
Parenchymal
loss
P
value
Immediate Renal Outcomes
Deterioration 10% 13% .31
No change 80% 82%
Improved 8% 5%
Cured 2% 1%
Long Term Renal
Outcomes
Increase in creatinine 16% 29% .0002
Progression to
hemodialysis 7% 17% .0001
Death from renal cause 2% 5% .052these immediate outcomes were not significant.Outcomes (>3 months). Thirty-one percent of the
kidneys suffered parenchymal loss in follow-up (median,
4.5 years; range, 1-14 years). There was a significant differ-
ence in median follow up, which can be accounted for by
the higher mortality rate in the Loss group compared with
the noLoss group. When the entire cohort was studied,
freedom from parenchymal loss was 74% at five years and
55% at 10 years (Fig 1A). There were differences based on
presenting symptoms with renal insufficiency having a
lower freedom from parenchymal loss compared with the
hypertensive group (Fig 1B). By multivariate analysis, a
history of hypertension (F  0.007, P  0.01), an eGFR
30 mL/min/1.73 m2 (F  0.02, P  .001), a RI 0.8
(F  0.02, P  .001), a nephrosclerosis score 2 (F 
0.01, P .001), and acute functional injury (F 0.01, P
.013) were associated with parenchymal loss. Cumulative
patency rates determined by serial duplex imaging were
98% 1% vs 98% 1% and 98% 3% vs 97% 5%, noLoss
vs Loss, at five and 10 years, respectively (Fig 2A). Rates of
restenosis were 93%  2% vs 87%  3% and 84%  5% vs
Fig 1. Parenchymal loss: Kaplan-Meier analysis of parenchymal
loss of each kidney treated for the entire cohort of patients (A) and
for patients presenting with hypertension, elevated creatinine or
Hypertension with elevated creatinine (B) patients. The number of
kidneys at risk at each time interval is shown below each figure.
Values are mean  standard error of the mean. Standard errors
exceeding 10% are not shown.69% 9%, noLoss vs Loss, at five and 10 years, respectively
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mal loss was significantly associated with a decrease in
survival (HR 1.76, 1.47-2.06, P  .001) and a decrease in
freedom from renal-related morbidity (HR 1.46, 0.33-
2.77, P  .01). Parenchymal loss was associated with
significantly worse 5 year survival (26% 4% vs 48% 2%;
Loss vs noLoss; P  .001) (Fig 3A) and with significantly
worse freedom from renal-related morbidity (70%  5% vs
82% 2%; P .05) with increased numbers progressing to
dialysis (17% vs 7%; P  .05) (Fig 3B and Table IV).
DISCUSSION
This is the largest study to examine parenchymal vol-
ume preservation in patients undergoing renal intervention
for symptomatic renal artery atherosclerotic disease. Vol-
ume preservation occurred in most kidneys, but volume
loss occurs in one third of patients after renal intervention
and is associated with pre-procedure markers of decreased
function and parenchymal perfusion. Parenchymal loss
is associated with markedly decreased survival and renal-
Fig 2. (A) Patency: Kaplan-Meier analysis of assisted primary
patency of the renal arteries with and without parenchymal loss.
(B) Restenosis: Kaplan-Meier analysis of freedom from restenosis
of the patients with and without parenchymal loss. The number at
risk at each time interval is shown below each figure. Values are
mean standard error of themean. Standard errors exceeding 10%
are not shown.related morbidity including progression to dialysis. For theclinician, an eGFR 30 mL/min/1.73 m2, a resistive
index 0.8, and a nephrosclerosis score 2 should be
considered as indicators of patients that are at risk of
parenchymal loss in follow-up.
Decreased renal parenchymal perfusion leads to isch-
emic nephropathy, which has as its hallmarks glomerular
atrophy, tubulo-interstitial lesions and fibrosis.13,14 It is
now recognized that severity of histopathologic damage is
an important determinant and predictor of renal functional
outcome. The classification of chronic renal disease stresses
the importance of proteinuria as a marker of renal disease.
Proteinuria increases with declining renal failure and re-
flects the severity of parenchymal damage. Proteinuria and
high renal resistance index are associated with glomerular
damage and altered intrarenal perfusion.15 Loss of paren-
chyma leads to renal atrophy. The risk of renal atrophy is
highest in patients with elevated systolic blood pressure,
high-grade renal artery atherosclerotic disease, and low
Fig 3. (A) Survival: Kaplan-Meier analysis of survival of the pa-
tients with and without parenchymal loss. (B) Renal related mor-
bidity: Kaplan-Meier analysis of freedom from renal related mor-
bidity (persistent increase in creatinine 20% of baseline,
progression to hemodialysis, death from renal-related causes) of
the patients with and without parenchymal loss. The number at
risk at each time interval is shown below each figure. Values are
mean standard error of themean. Standard errors exceeding 10%
are not shown.renal cortical blood flow velocity as assessed by renal duplex
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serum creatinine concentration. Unilateral hemodynami-
cally significant atherosclerotic renal artery disease is also
associated with the development of arteriolar nephroscle-
rosis in the contralateral kidney, thus leading to a global
effect on renal related morbidity.17 In the current study, we
found that markers of decreased renal perfusion were asso-
ciated with parenchymal loss. We also noted that the con-
tralateral kidney was significantly smaller and also had
markers of decreased renal perfusion, supporting the con-
tention that the contralateral kidney is also affected by
significant atherosclerotic renal artery disease. In the cur-
rent study, bilateral disease was treated when indicated
using the same criteria as the ipsilateral side.
This study concentrated on renal volume as marker of
end organ protection. There has been an increasing interest
in modeling the changes in the organ in three dimensions
(3-D). Three-dimensional parameters of parenchymal vol-
ume are stronger correlates of radioisotopic measurement of
single-kidney GFR than two-dimensional measures of renal
bipolar length, parenchymal thickness, and cortical thick-
nesses.6,18 Interestingly, kidneys supplied by moderately
stenosed arteries have enlarged lengths and volumes, while
those supplied by severely stenosed arteries have signifi-
cantly smaller lengths and volumes. There is a clear associ-
ation between magnetic resonance imaging (MRI) cortical
volume and GFR, but less so between kidney length and
GFR.7 In a proportion of kidneys with 50% atheroscle-
rotic renal artery stenosis, a disproportionately high paren-
chymal volume to radioisotopic measurement of single-
kidney GFR has been observed supporting a concept of
‘hibernating parenchyma.’ We did not explore this concept
in the current retrospective study. Kidneys with increased
parenchymal volume to single kidney-GFRmight represent
a subgroup with the potential to respond beneficially to
intervention.6 In contrast, these studies did not identify
kidneys at risk of further parenchymal loss.
There was no association of non-renal co-morbid con-
ditions and outcomes. Patients with parenchymal loss did
have worse renal function as indicated by their lower eGFR
and higher kidney stages. Renal artery stenosis is an inde-
pendent predictor of mortality. At seven years, 73% of
patients with untreated renal artery stenosis are dead.19 The
seven-year actuarial mortality in this study for patients with
no parenchymal loss was 33% and with parenchymal loss
was 61%, which is significantly better than the historically
reported data for untreated disease. This is similar to a
previous study in which we noted for the outcomes of acute
functional injury (seven-year actuarial mortality for acute
functional injury was 68% and for no acute functional injury
was 37%).9 Similar to the current study, immediate and
long-term post procedure creatinine deterioration and di-
alysis dependency have been associated with increasedmor-
tality.1-3,9 Identification of parenchymal preservation may
be a marker of survival benefit in those undergoing renal
artery intervention.
There was no difference in technical success between
the groups. The mode of intervention was also similar.Patency was the same in both groups. The results of the
current study are within the ranges of a meta-analysis of
primary renal artery stenting that documented a technical
success of 96% to 100% and restenosis rates following
primary stenting ranging from 9% and 39% at six and 12
months, respectively.20 However, the freedom from reste-
nosis in the parenchymal loss group was higher over time
than the no parenchymal loss group. This restenosis was
not mirrored by an increase in ipsilateral re-intervention
rates. Mounier-Vehier et al have shown that there was an
11% drop in cortical atrophy associated with a mean 4 mm
increase in medullary length in the poststenotic/revascu-
larized kidneys and that the contralateral kidneys exhibit
continued cortico-medullary thinning.21 While reports on
a renal resistance-index value 0.8 suggest it can reliably
identify patients in whom intervention will not improve
blood pressure,22 there remains controversy if it can reliably
predict post intervention renal function response or kidney
survival.22,23 Girndt et al have noted that a decrease in renal
function over time is significantly higher in patients with
flow enhancement (a flow velocity of 2.0 m/s) and that
there is a high rate of in-stent restenosis associated with
enhanced loss of renal function.24 We did see a higher rate
of restenosis in the group that suffered parenchymal loss. A
recent study of magnetic resonance (MR)-based renal ar-
tery flow measurements and renal parenchymal volume has
demonstrated that normal kidney volume results in a high
sensitivity (91%) but a low specificity (33%) for a response
to renal intervention defined as a reduction in diastolic
blood pressure 15% or a reduction in serum creatinine
 20%.25 A renal flow index (RFI) calculated by dividing
the renal flow (mL/min) by the renal volume (cm3) below
a threshold of 1.5 mL/min/cm3 predicted successful out-
come with 100% sensitivity but 33% specificity. A combi-
nation of normal renal volume and a RFI below 1.5 mL/
min/cm3 identified percutaneous intervention responders
with a sensitivity of 91% and a specificity of 67%. Negative
predictive values were high at 100%, 89%, and 89% for renal
volume, renal flow index, and the composite score, respec-
tively.25 In the current study, we have shown that an
elevated resistive index with a worsening nephrosclerosis
score was associated with parenchymal loss.
The most significant finding in this study is that the
patient survival and renal related morbidity were signifi-
cantly worse in patients with parenchymal loss. We previ-
ously identified the presence of higher grade of nephroscle-
rosis in patients, who subsequently suffered acute
functional injury suggesting that irreversible changes
were already present and that intervention was unlikely to
benefit the patient.9 Patients who developed parenchymal
loss had a significantly higher incidence of acute functional
injury after intervention. After simple angioplasty in all
comers, improvement or stabilization of the renal functions
has been reported to range from 38% to 100%26-29 andwith
primary stent placement, improvement or stabilization of
the renal functions has been reported as ranging from 24%
to 100%.30-36 It can be argued that embolic debris may
have contributed to the parenchymal loss observed due to
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curred in the parenchymal loss group. In patients with the
defined risk factors of low eGFR, high resistive index and
high nephrosclerosis score and use of an embolic protection
device may be of benefit. Early experience with distal pro-
tection devices suggests that retrieval of embolic material
will occur in approximately 60% to 70% of cases and renal
functional improvement/stabilization in 98% of cases.37-39
Captured particle sizes60 micrometers in a patient with a
poor pre-procedure eGFR were associated with inferior
renal function results post procedure. In patients with renal
insufficiency, endovascular intervention using distal pro-
tection device resulted in 4- to 6-week post-intervention
renal function results approximating those of surgical
revascularization.40 This study suggests that an eGFR30
mL/min/1.73 m2, a resistive index 0.8, and a nephro-
sclerosis score 2 should be considered as indicators of
patients that are at risk of parenchymal loss andwhere use of
an embolic protection device may be considered beneficial.
This premise will need to be tested in a formal study.
This study is a retrospective study and as such suffers
from multiple limitations. The population treated was het-
erogeneous with a low proportion of patients presenting
with an elevated creatinine and no control group. Patients
with lower eGFR may have smaller renal volumes prior to
treatment and this may alter renal volume preservation.
eGFR decreases with age and thus there may be a natural
drop in renal volume over time, for which we have not
accounted. The study period also encompasses a rise in
renal interventions, changes in pre-procedure preparations,
changes in contrast composition, and refinements in imag-
ing systems and delivery systems.
CONCLUSION
While parenchymal preservation occurs in most pa-
tients, parenchymal loss occurs in 31% of patients and is
associated with markers of impaired parenchymal perfusion
(resistive index and nephrosclerosis grade) at the time of
intervention. Pre-existing renal size or volumes were not
predictive of parenchymal loss. Parenchymal loss is associ-
ated with a significant decrease in survival and a marked
increased renal related morbidity and progression to hemo-
dialysis.
We thank Daynene Vykoukal, PhD, The Methodist
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ing mauscript preparation.
AUTHOR CONTRIBUTIONS
Conception and design: MD
Analysis and interpretation: WS, MD
Data collection: EP, JN, WS, AL, MD
Writing the article: WS, AL, MD
Critical revision of the article: EP, JN, WS, AL, MD
Final approval of the article: EP, JN, WS, AL, MD
Statistical analysis: WS, MD
Obtained funding: MD
Overall responsibility: MDREFERENCES
1. Sivamurthy N, Suroweic SM, Culakova E, Rhodes JM, Lee D, Stern-
bach Y, et al. Divergent outcomes after percutaneous therapy for
symptomatic renal artery stenosis. J Vasc Surg 2004;39:565-74.
2. Yutan E, Glickerman DJ, Caps MT, Hatsukami T, Harley JD, Davies
MG. Percutaneous transluminal revascularization for renal artery steno-
sis: Veterans Affairs Puget SoundHealth Care System experience. J Vasc
Surg 2001;34:685-93.
3. Galaria, II, Surowiec SM, Rhodes JM, Illig KA, Shortell CK, Sternbach
Y, et al. Percutaneous and open renal revascularizations have equivalent
long-term functional outcomes. Ann Vasc Surg 2005;19:218-28.
4. Hansen KJ, Cherr GS, Craven TE, Motew SJ, Travis JA, Wong JM,
et al. Management of ischemic nephropathy: dialysis-free survival
after surgical repair. J Vasc Surg 2000;32:472-82.
5. Kashyap VS, Sepulveda RN, Bena JF, Nally JV, Poggio ED, Greenberg
RK, et al. The management of renal artery atherosclerosis for renal
salvage: does stenting help? J Vasc Surg 2007;45:101-8.
6. Cheung CM, Shurrab AE, Buckley DL, Hegarty J, Middleton RJ,
Mamtora H, et al. MR-derived renal morphology and renal function in
patients with atherosclerotic renovascular disease. Kidney Int 2006;69:
715-22.
7. Gandy SJ, Armoogum K, Nicholas RS, McLeay TB, Houston JG. A
clinical MRI investigation of the relationship between kidney volume
measurements and renal function in patients with renovascular disease.
Br J Radiol 2007;80:12-20.
8. Rasmussen SN, Haase L, Kjeldsen H, Hancke S. Determination of renal
volume by ultrasound scanning. J Clin Ultrasound 1978;6:160-4.
9. Davies MG, Saad WE, Peden EK, Mohiuddin IT, Naoum JJ, Lumsden
AB. Implications of acute renal injury following percutaneous renal
artery intervention. Ann Vasc Surg 2008;22:783-9.
10. Rundback JH, Sacks D, Kent KC, Cooper C, Jones C,Murphy TP, et al.
Guidelines for the reporting of renal artery revascularization in clinical
trials. Circulation 2002;106:1572-85.
11. Grundy SM, Brewer HBJ, Cleeman JI, for the Conference Participants.
Definition of metabolic syndrome: report of the National Heart, Lung,
and Blood Institute/American Heart Association conference on scien-
tific issues related to definition. Circulation 2004;109:433-8.
12. Hansen KJ, Thomason RB, Craven TE, Fuller SB, KeithDR, Appel RG,
et al. Surgical management of dialysis-dependent ischemic nephropa-
thy. J Vasc Surg 1995;21:197-211.
13. Meyrier A. Renal vascular lesions in the elderly: nephrosclerosis or
atheromatous renal disease? Nephrol Dial Transplant 1996;11(Suppl
9):45-52.
14. Dean RH, Tribble RW, Hansen KJ, et al. Evolution of renal insuffi-
ciency in ischaemic nephropathy. Ann Surg 1991;213:446-55.
15. Flisin´ski M, Manitius J. Predictors of successful renal artery revascular-
ization in atherosclerotic renovascular disease. Pol Merkur Lekarski
2005;19:206-10.
16. Caps MT, Zierler RE, Polissar NL, Bergelin RO, Beach KW, Cantwell-
Gab K, et al. Risk of atrophy in kidneys with atherosclerotic renal artery
stenosis. Kidney Int 1998;53:735-42.
17. TullisMJ, Zierler RE, CapsMT, Bergelin RO, Cantwell-Gab K, Strand-
ness DEJ. Clinical evidence of contralateral renal parenchymal injury in
patients with unilateral atherosclerotic renal artery stenosis. Ann Vasc
Surg 1998;12:122-7.
18. Widjaja E, Oxtoby JW, Hale TL, Jones PW, Harden PN, McCall IW.
Ultrasound measured renal length versus low dose CT volume in
predicting single kidney glomerular filtration rate. Br J Radiol 2004;77:
759-64.
19. Zierler RE, Bergelin RO, Davidson RC, Cantwell-Gab K, Polissar NL,
Strandness DEJ. A prospective study of disease progression in patients
with atherosclerotic renal artery stenosis. Am J Hypertension 1996;9:
1055-61.
20. Isles CG, Robertson S, Hill D. Management of renovascular disease: a
review of renal artery stenting in ten studies. Q JMed 1999;92:159-67.
21. Mounier-Vehier C, Haulon S, Devos P , et al. Renal atrophy outcome
after revascularization in fibromuscular dysplasia disease. J Endovasc
Ther 2002;9:605-13.
JOURNAL OF VASCULAR SURGERY
Volume 51, Number 5 Davies et al 122922. Radermacher J, Chavan A, Bleck J, Vitzthum A, Stoess B, Gebel MJ,
et al. Use of Doppler ultrasonography to predict the outcome of
therapy for renal-artery stenosis. N Engl J Med 2001;344:410-7.
23. García-Criado A, Gilabert R, Nicolau C, Real MI, Muntañá X,
Blasco J, et al. Value of Doppler sonography for predicting clinical
outcome after renal artery revascularization in atherosclerotic renal
artery stenosis. J Ultrasound Med 2005;24:1641-7.
24. GirndtM, KaulH,Maute C, Kramann B, KöhlerH,UderM. Enhanced
flow velocity after stenting of renal arteries is associated with decreased
renal function. Nephron Clin Pract 2007;105:c84-9.
25. Binkert CA, Debatin JF, Schneider E, Hodler J, Ruehm SG, Schmidt
M, et al. Can MR measurement of renal artery flow and renal volume
predict the outcome of percutaneous transluminal renal angioplasty?
Cardiovasc Intervent Radiol 2001;24:233-9.
26. Leertouwer TC, Gussenhoven EJ, Bosch JL, VanJaarveld BC, Van
Dijk LC, Delnum, J, ManIn’tVeld AJ. Stent placement for renal
arterial stenosis: where do we stand? A meta-analysis. Radiology
2000;216:78-85.
27. Plouin PF, Chatellier G, Darne B, Raynoud A. Blood pressure outcome
of angioplasty in atherosclerotic renal artery stenosis: a randomized trial.
Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study
Group. Hypertension 1998;31:823-9.
28. Hoffman O, Carreres T, Sapoval MR, Auguste MC, Beyssen BM,
Raynaud AC, et al. Ostial renal artery stenosis angioplasty: immediate
and mid-term angiographic and clinical results. J Vasc Interv Radiol
1998;9:65-73.
29. Jensen G, Zachrisson BF, Delin K, Volkmann R, Aurell M. Treatment
of renovascular hypertension: one year results of renal angioplasty.
Kidney Int 1995;48:1936-45.
30. Chatziioannou A, Mourikis D, Agroyannis B, Katsenis K, Pneumaticos S,
Antoniou A, et al. Renal artery stenting for renal insufficiency in solitary
kidney in 26 patients. Eur J Vasc Endovasc Surg 2002;23:49-54.
were more likely to present with an elevated creatinine and with31. Cioni R, Vignali C, Petruzzi P, Neri E, Caramella D, Vagli P, et al.
Renal artery stenting in patients with a solitary functioning kidney.
Cardiovasc Intervent Radiol 2001;24:372-7.
32. Taylor A, Sheppard D, MacLeod MJ, Harden P, Baxter GM, Edwards
RD, et al. Renal artery stent placement in renal artery stenosis: technical
and early clinical results. Clin Radiol 1997;52:451-7.
33. Lederman RJ, Mendelsohn FO, Santos R, Phillips HR, Stack RS,
Crowley J. Primary renal artery stenting: characteristics and outcomes
after 363 procedures. Am Heart J 2001;142:314-23.
34. Dorros G, Jaff M, Mathiak L. Four-year follow-up of PalmazSchatz
stent revascularization as treatment for atherosclerotic renalartery ste-
nosis. Circulation 1998;98:642-7.
35. Rocha-Singh KJ, Ahuja RK, Sung CH, Rutherford J. Long-term
renal function preservation after renal artery stenting in patients with
progressive ischemic nephropathy. Catheter Cardiovasc Interv 2002;
57:135-41.
36. Hennequin LM, Joffre FG, RousseauHP, Aziza R, Tregant P, Bernadet
P, et al. Renal artery stent placement: long-term results with the
Wallstent endoprosthesis. Radiology 1994;191:713-9.
37. Dubel GJ, Murphy TP. Distal embolic protection for renal arterial
interventions. Cardiovasc Intervent Radiol 2008;31:14-22.
38. Holden A, Hill A. Renal angioplasty and stenting with distal protec-
tion of the main renal artery in ischemic nephropathy: early experi-
ence. J Vasc Surg 2003;38:962-8.
39. Holden A, Hill A, Jaff MR, Pilmore H. Renal artery stent revasculariza-
tion with embolic protection in patients with ischemic nephropathy.
Kidney Int 2006;70:830-2.
40. Edwards MS, Craven BL, Stafford J, Craven TE, Sauve KJ, Ayerdi J,
et al. Distal embolic protection during renal artery angioplasty and
stenting. J Vasc Surg 2006;44:128-35.Submitted Jul 27, 2009; accepted Sep 21, 2009.DISCUSSION
Dr Ali AbuRahma (Charleston, WV). This is a very interest-
ing presentation because we always hear about renal function
improvement after renal stenting, but not specifically about
parenchymal preservation. I may have missed this in your pre-
sentation, but did you notice any correlation between preoper-
ative serum creatinine and improvement after renal stenting (eg,
creatinine of 2.5 vs 1.5 to 2.0 and so forth)? I am asking this
question because a couple of years ago we analyzed the results of
196 renal stents done at our institution, and we found that
serum creatinine of 2.0 was predictive of stabilization or im-
provement of renal function. If it was below 2.0, it did not make
a difference at all.
Dr Mark Davies. We did not look at serum creatinine. The
literature now is moving toward using estimated glomerular filtra-
tion rate as a more appropriate marker of renal function. If patients
had an estimated glomerular filtration rate of less than 30, there
was a significant correlation with subsequent parenchymal loss.
Dr Joseph Schneider (Winfield, Ill). Was I correct to see in
your slide that no parenchymal loss was associated with a higher
rate of hypertension?
Dr Davies. Correct. The patients who had parenchymal losscontralateral disease. Hypertension did not fall out as a predictor of
parenchymal loss.
Dr Richard Cambria (Boston, Mass). You’ve described what
are likely predictable changes after the intervention that corre-
late with clinically relevant outcomes, but how about for clinical
decision-making–your data beforehand, do you have renal resistive
indices pretreatment on all your patients, and was that examined,
for example, with outcome? So in terms of decision-making, I
think we would like to know more about the pretreatment param-
eters that might relate to clinical responses.
DrDavies. An estimated glomerular filtration rate of less than
30, resistive index 0.8, and worst nephrosclerosis grade were
linked to subsequent parenchymal loss. Parenchymal loss is linked
to renal-related morbidity and decreased survival.
Dr Robert Cambria (Bangor, Me). Your data on the con-
tralateral kidney went by quite quickly and I didn’t really see it. I
wonder if you could compare for us the changes you saw in stented
kidneys versus nonstented kidneys, and was there any effect of the
stent? Did nonstented kidneys lose parenchyma faster than stented
kidneys?
Dr Davis. We did not include that data in the study, but the
contralateral kidneys were smaller than the ipsilateral kidneys at the
beginning of the study.
